222 related articles for article (PubMed ID: 35443747)
21. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.
He WT; Musharrafieh R; Song G; Dueker K; Tse LV; Martinez DR; Schäfer A; Callaghan S; Yong P; Beutler N; Torres JL; Volk RM; Zhou P; Yuan M; Liu H; Anzanello F; Capozzola T; Parren M; Garcia E; Rawlings SA; Smith DM; Wilson IA; Safonova Y; Ward AB; Rogers TF; Baric RS; Gralinski LE; Burton DR; Andrabi R
Nat Immunol; 2022 Jun; 23(6):960-970. PubMed ID: 35654851
[TBL] [Abstract][Full Text] [Related]
22. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies.
Zhang F; Jenkins J; de Carvalho RVH; Nakandakari-Higa S; Chen T; Abernathy ME; Baharani VA; Nyakatura EK; Andrew D; Lebedeva IV; Lorenz IC; Hoffmann HH; Rice CM; Victora GD; Barnes CO; Hatziioannou T; Bieniasz PD
Nat Microbiol; 2023 Jun; 8(6):1051-1063. PubMed ID: 37188812
[TBL] [Abstract][Full Text] [Related]
23. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
24. Superimmunity by pan-sarbecovirus nanobodies.
Xiang Y; Huang W; Liu H; Sang Z; Nambulli S; Tubiana J; Williams KL; Duprex WP; Schneidman-Duhovny D; Wilson IA; Taylor DJ; Shi Y
Cell Rep; 2022 Jun; 39(13):111004. PubMed ID: 35738279
[TBL] [Abstract][Full Text] [Related]
25. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice.
Martinez DR; Schäfer A; Gobeil S; Li D; De la Cruz G; Parks R; Lu X; Barr M; Stalls V; Janowska K; Beaudoin E; Manne K; Mansouri K; Edwards RJ; Cronin K; Yount B; Anasti K; Montgomery SA; Tang J; Golding H; Shen S; Zhou T; Kwong PD; Graham BS; Mascola JR; Montefiori DC; Alam SM; Sempowski G; Sempowski GD; Khurana S; Wiehe K; Saunders KO; Acharya P; Haynes BF; Baric RS
Sci Transl Med; 2022 Jan; 14(629):eabj7125. PubMed ID: 34726473
[TBL] [Abstract][Full Text] [Related]
26. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
27. A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape.
Feng B; Chen Z; Sun J; Xu T; Wang Q; Yi H; Niu X; Zhu J; Fan M; Hou R; Shao Y; Huang S; Li C; Hu P; Zheng P; He P; Luo J; Yan Q; Xiong X; Liu J; Zhao J; Chen L
Small Methods; 2022 Jul; 6(7):e2200387. PubMed ID: 35583124
[TBL] [Abstract][Full Text] [Related]
28. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
[TBL] [Abstract][Full Text] [Related]
29. Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design.
Hauser BM; Feldman J; Sangesland M; Ronsard L; St Denis KJ; Sheehan ML; Cao Y; Boucau J; Windsor IW; Cheng AH; Vu ML; Cardoso MR; Kannegieter T; Balazs AB; Lingwood D; Garcia-Beltran WF; Schmidt AG
Cell Rep Med; 2022 Dec; 3(12):100834. PubMed ID: 36423634
[TBL] [Abstract][Full Text] [Related]
30. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
[TBL] [Abstract][Full Text] [Related]
31. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination.
Zhao X; Qiu T; Huang X; Mao Q; Wang Y; Qiao R; Li J; Mao T; Wang Y; Cun Y; Wang C; Luo C; Yoon C; Wang X; Li C; Cui Y; Zhao C; Li M; Chen Y; Cai G; Geng W; Hu Z; Cao J; Zhang W; Cao Z; Chu H; Sun L; Wang P
Cell Discov; 2024 Feb; 10(1):14. PubMed ID: 38320990
[TBL] [Abstract][Full Text] [Related]
32. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
33. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
Front Immunol; 2022; 13():863831. PubMed ID: 35547740
[TBL] [Abstract][Full Text] [Related]
34. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
[TBL] [Abstract][Full Text] [Related]
35. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Walls AC; Miranda MC; Pham MN; Schäfer A; Greaney A; Arunachalam PS; Navarro MJ; Tortorici MA; Rogers K; O'Connor MA; Shireff L; Ferrell DE; Brunette N; Kepl E; Bowen J; Zepeda SK; Starr T; Hsieh CL; Fiala B; Wrenn S; Pettie D; Sydeman C; Johnson M; Blackstone A; Ravichandran R; Ogohara C; Carter L; Tilles SW; Rappuoli R; O'Hagan DT; Van Der Most R; Van Voorhis WC; McLellan JS; Kleanthous H; Sheahan TP; Fuller DH; Villinger F; Bloom J; Pulendran B; Baric R; King N; Veesler D
bioRxiv; 2021 Mar; ():. PubMed ID: 33758839
[TBL] [Abstract][Full Text] [Related]
36. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif.
Hauser BM; Sangesland M; Lam EC; Denis KJS; Feldman J; Yousif AS; Caradonna TM; Kannegieter T; Balazs AB; Lingwood D; Schmidt AG
bioRxiv; 2021 Jun; ():. PubMed ID: 33330872
[TBL] [Abstract][Full Text] [Related]
37. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice.
Martinez DR; Schaefer A; Gobeil S; Li D; De la Cruz G; Parks R; Lu X; Barr M; Manne K; Mansouri K; Edwards RJ; Yount B; Anasti K; Montgomery SA; Shen S; Zhou T; Kwong PD; Graham BS; Mascola JR; Montefiori DC; Alam M; Sempowski GD; Wiehe K; Saunders KO; Acharya P; Haynes BF; Baric RS
bioRxiv; 2021 Apr; ():. PubMed ID: 33948590
[TBL] [Abstract][Full Text] [Related]
38. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
[TBL] [Abstract][Full Text] [Related]
39. Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants.
Chen Z; Zhang P; Matsuoka Y; Tsybovsky Y; West K; Santos C; Boyd LF; Nguyen H; Pomerenke A; Stephens T; Olia AS; De Giorgi V; Holbrook MR; Gross R; Postnikova E; Garza NL; Johnson RF; Margulies DH; Kwong PD; Alter HJ; Buchholz UJ; Lusso P; Farci P
medRxiv; 2022 Jan; ():. PubMed ID: 35043120
[TBL] [Abstract][Full Text] [Related]
40. Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection.
Ekström N; Haveri A; Solastie A; Virta C; Österlund P; Nohynek H; Nieminen T; Ivaska L; Tähtinen PA; Lempainen J; Jalkanen P; Julkunen I; Palmu AA; Melin M
Open Forum Infect Dis; 2022 Dec; 9(12):ofac625. PubMed ID: 36519113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
